38 news items
U.S. FDA Approves SKYRIZI® (risankizumab-rzaa) for Ulcerative Colitis, Expanding AbbVie's Portfolio Across Inflammatory Bowel Disease
ABBV
18 Jun 24
the efficacy and safety of risankizumab 1200 mg IV administered every four weeks as induction therapy in subjects with moderately to severely active
Pharma Stock Roundup: FDA Panel Endorses LLY's Donanemab, PFE's DMD Therapy Study Fails
ABBV
AZN
LLY
14 Jun 24
outweighed the risks despite some safety concerns. Anti-amyloid antibodies like donanemab can cause a brain swelling side effect called amyloid-related
BOTOX® Cosmetic (onabotulinumtoxinA) Reveals 2024 Women Entrepreneur Grant Recipients
ABBV
11 Jun 24
COSMETIC IMPORTANT SAFETY INFORMATION AND APPROVED USES
Approved
Goldman Sachs Optimistic About Regenxbio's Gene Therapy Pipeline, Sees Over 160% Upside
ABBV
FDMT
REGN
7 Jun 24
to the high standards of efficacy and safety set by newer anti-VEGF treatments that require fewer injections, e.g., high dose Regeneron
AbbVie's Immunogen Acquired Elahere Meets Primary Goal In Mid-Stage Study In Heavily Pretreated Ovarian Cancer Patients
ABBV
6 Jun 24
secondary endpoint, was 8.25 months.
The safety profile of mirvetuximab soravtansine was consistent with previous studies’ findings
mdlw2kg5t6w9plxpzv4qb8griibkhyzig1m2ba8oj77em9
ABBV
6 Jun 24
(DOR), a key secondary endpoint, was 8.25 months.The safety profile of mirvetuximab soravtansine was consistent with findings from previous
d4tq8x9judupqyn7wkd25
ABBV
6 Jun 24
(DOR), a key secondary endpoint, was 8.25 months.
The safety profile of mirvetuximab soravtansine
6k69dzz7ils51bwmd35b6pldwx2m77z98wg31s2sqly09xuhtjba
ABBV
6 Jun 24
.
BOTOX® COSMETIC IMPORTANT SAFETY INFORMATION
77ufhm 3m33nlmz
ABBV
5 Jun 24
(r/r MM) The CERVINO Phase 3 trial will evaluate the efficacy, safety, and tolerability of ABBV-383 monotherapy compared
pm41u1x4szivzii7 cki2hwukd5t5rps
ABBV
5 Jun 24
Phase 3 trial will evaluate the efficacy, safety, and tolerability of ABBV-383 monotherapy compared with standard available
9dadiuauwretzk0wiv0afmd atxvy
ABBV
4 Jun 24
with active polyarthritis, in addition to safety data from 83 pediatric patients two to less than 18 years of age with juvenile idiopathic arthritis
b05jsy42n0kearl7hj8kcv6jv61oi4zr0992zm06h3az9l75usp1euv
ABBV
4 Jun 24
SAFETY
v72qb txp
ABBV
31 May 24
The positive opinion is based on results from two pivotal Phase 3 trials, INSPIRE and COMMAND, that evaluated the efficacy and safety
9fx4qclodjfba haagvvecf5fe1e6phcwwowar9
ABBV
31 May 24
opinion is based on results from two pivotal Phase 3 trials, INSPIRE and COMMAND, that evaluated the efficacy and safety of risankizumab in adults
dnbbcsxg71v6 zz
ABBV
28 May 24
New safety and efficacy data in heavily pre-treated patients with metastatic colorectal cancer (CRC), from a Phase 1 study of ABBV-400
6lrxixmerlc 490hdm
ABBV
CYTO
ONCY
24 May 24
Questionnaire, p < 0.001) and superior global ratings of efficacy by patients and investigators alike (p < 0.001). In addition, Bentrio showed good safety
42um47nybycwpk0ldhov5v1lahlqoqp4rry
ABBV
LABP
23 May 24
, or placebo. The primary objective of the trial will be to evaluate clinical efficacy, safety and pharmacokinetics of oral NX-13 versus placebo (NCT05785715
c78bxqvz8twz3cd2t47yzasjpr4pnh3l0fwvsg7a7
ABBV
AMGN
CURLF
18 May 24
by licensed pharmacists, aiming to ensure patient safety and product consistency.
To learn more about all of this and how to invest
qvt3grjz05n crzp6cks232
ABBV
BMY
17 May 24
dosing frequency (QD vs. BD), better GI safety profile, and potentially greater efficacy (PANSS score),” Cantor writes.
The analyst says
835nldb 3e2s
ABBV
17 May 24
presentations include efficacy and safety data evaluating clinical, endoscopic, and histologic outcomes from both the INSPIRE Phase 3 induction study